A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Stay updated with breaking news from Cll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Researchers found that venetoclax, either alone or post treatment with a Bruton tyrosine kinase inhibitor (BTKi), was safe and effective for patients with chronic lymphocytic leukemia (CLL).
Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).
Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).
Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.